Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FedEx cuts FY revenue forecasts amid weak demand

(Sharecast News) - Logistics firm FedEx was in the red early on Wednesday after it cut revenue forecasts amid weaker demand. FedEx now expects to report a low-single-digit revenue decline for the full year, down from previous forecasts for flat year-on-year sales, and the second consecutive quarter the company has lowered its sales outlook.

The Memphis-based company noted that its express unit, its largest, was particularly challenged during the second quarter as iii navigated lower demand, surcharges, and customers shifting to cheaper services.

For the three months ended 30 November, net income came to $900.0m, or $3.55 per share, versus $788.0m a year earlier, while adjusting for certain items, FedEx posted earnings of $1.01bn, up more than 25% year-on-year but short of Wall Street estimates.

FedEx cited cost-cutting initiatives for its higher profit, which came even as quarterly revenues fell 3% to $22.17bn.

Chief executive Raj Subramaniam said: "When you step back and review how our business has performed in environments with suppressed demand, we are delivering much better profitability today than we have historically."

As of 1525 GMT, FedEx shares were down 10.98% at $252.16 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.
McCarthy out, Adshead in as Ultimate Products chair
(Sharecast News) - Ultimate Products, the parent of homeware brands including Salter and Beldray, announced a change in its leadership on Monday, with James 'Jim' McCarthy deciding to step down as non-executive chair from 31 July.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.